# Implementation of a Personalized Medicine Approach in Patients With Type 2 Diabetes Mellitus Receiving Multiple Daily Insulin Injections (POMA Project): Protocol for a Before-and-After Intervention Study

## TL;DR

This study tests a personalized diabetes treatment protocol to simplify insulin therapy for type 2 diabetes patients.

## Contribution

A novel personalized medicine protocol using C-peptide and autoantibody testing to optimize insulin therapy in type 2 diabetes.

## Key findings

- The protocol aims to discontinue prandial insulin in eligible patients without compromising glycemic control.
- CGM data and autoimmunity testing will guide treatment adjustments in real-world clinical settings.
- The study will assess feasibility and outcomes of personalized diabetes care over six months.

## Abstract

The management of type 2 diabetes mellitus (T2DM) remains a complex clinical challenge, particularly for patients requiring multiple daily insulin injections (MDI). Advances in precision medicine and continuous glucose monitoring (CGM) have created opportunities to personalize treatment and potentially reduce the therapeutic burden on people with T2DM. Assessing β cell function and autoimmunity could help identify patients with T2DM eligible for simplified regimens without compromising glycemic control.

The aim of this study is to test a simple personalized medicine protocol in routine clinical practice for people with T2DM treated with MDI. The intervention is based on evaluating C-peptide and glutamic acid decarboxylase autoantibody status with the goal of improving diagnostic accuracy and optimizing treatment.

This is a pragmatic before-and-after intervention study involving people with T2DM currently receiving MDI across primary care centers and a referral hospital in the Lleida health care region in Catalonia (Spain). Eligible participants will undergo clinical and laboratory assessment, including C-peptide and glutamic acid decarboxylase autoantibody testing, and wear a CGM device. On the basis of a predefined algorithm, patients may either continue or discontinue prandial insulin. The primary outcome is the proportion of patients in whom prandial insulin is discontinued and remains discontinued over 6 months. Secondary outcomes include changes in hemoglobin A1c, CGM metric variables, quality of life, adherence, and treatment satisfaction.

Recruitment was completed on March 31, 2025. The follow-up phase is ongoing and expected to conclude by September 30, 2025. Data analysis will begin thereafter.

This study will evaluate the feasibility and impact of implementing a personalized therapeutic approach for persons with T2DM receiving MDI in real-world clinical settings. If effective, this strategy could contribute to safer, simpler, and more individualized diabetes care.